Publications by authors named "Warren Wen"

Claim this Profile
S
Systemic Inflammatory Markers Correlate with Chronic Kidney Disease-Associated Pruritus and Response to Treatment.
Robert H Spencer, Stephen A Kilfeather, Elaine Lee, Catherine Munera, Warren Wen

J Invest Dermatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of concomitant opioids on difelikefalin treatment outcomes in adults with moderate-to-severe pruritus on maintenance hemodialysis: Exploratory analyses.
James O Burton, Satkiran Grewal, Thilo Schaufler, Despina Ruessmann, Murray Lowe, Warren Wen

Kidney Blood Press Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric validation and meaningful change thresholds of the Skindex-10 questionnaire and 5-D Itch scale for assessing itch in patients with chronic kidney disease-associated pruritus.
Margaret K Vernon, Catherine Munera, Robert H Spencer, Warren Wen, Frédérique Menzaghi

J Patient Rep Outcomes· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Baseline Itch Severity on Treatment Outcomes With Difelikefalin in Adults With Moderate-to-Severe Pruritus Receiving Maintenance Haemodialysis: An Exploratory Analysis.
Kieran McCafferty, Thilo Schaufler, Pablo Molina, Murray Lowe, Warren Wen

J Ren Care· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic kidney disease-associated pruritus and quality of life with difelikefalin treatment: a analysis of phase 3 data using the Skindex-10 questionnaire.
Sonja Ständer, Steven Fishbane, Thilo Schaufler, Despina Ruessmann, Isabelle Morin, Warren Wen

Clin Kidney J· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies.
Steven N Fishbane, Geoff A Block, Pieter Evenepoel, Jeffrey Budden, Isabelle Morin, Warren Wen

Kidney360· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.
Daniel E Weiner, Thilo Schaufler, Kieran McCafferty, Kamyar Kalantar-Zadeh, Michael Germain, Warren Wen

Nephrol Dial Transplant· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2.
Steven Fishbane, Deborah J Clegg, Edgar V Lerma, Anjay Rastogi, Jeffrey Budden, Warren Wen

Am J Nephrol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CKD-Associated Pruritus and Clinical Outcomes in Nondialysis CKD.
Jennifer S Scherer, Charlotte Tu, Ronald L Pisoni, Elodie Speyer, Antonio A Lopes, Warren Wen

Kidney Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Burden of Pruritus Associated With CKD: A Mixed Methods Analysis Among Patients Undergoing Dialysis.
Frédérique Menzaghi, Margaret K Vernon, Maria Mattera, Joshua Cirulli, Warren Wen

Kidney Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study.
Daniel E Weiner, Marc G Vervloet, Sebastian Walpen, Thilo Schaufler, Catherine Munera, Warren Wen

Kidney Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.
Joel Topf, Thomas Wooldridge, Kieran McCafferty, Michael Schömig, Botond Csiky, Warren Wen

Kidney Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program.
Steven Fishbane, Warren Wen, Catherine Munera, Rong Lin, Sukirti Bagal

Kidney Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
Margaret K Vernon, Laura L Swett, Rebecca M Speck, Catherine Munera, Robert H Spencer, Warren Wen

J Patient Rep Outcomes· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients.
Nidhi Sukul, Angelo Karaboyas, Philipp A Csomor, Thilo Schaufler, Warren Wen

Kidney Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
Steven Fishbane, Aamir Jamal, Catherine Munera, Warren Wen, Frédérique Menzaghi

N Engl J Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness and safety of once-daily, single-entity, extended-release hydrocodone in patients of ≥75 years of age with moderate to severe nonmalignant and nonneuropathic pain.
Kathleen Broglio, Joseph Pergolizzi, Maribeth Kowalski, Shau Yu Lynch, Ellie He, Warren Wen

Geriatr Nurs· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.
Kathleen Campbell, J Walter Kutz, Angela Shoup, Warren Wen, Shau Yu Lynch

Pain Physician· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Once-Daily Extended-Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain.
Kathleen Broglio, Joseph Pergolizzi, Maribeth Kowalski, Shau Yu Lynch, Ellie He, Warren Wen

Pain Pract· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.
Robert R Edwards, Robert H Dworkin, Dennis C Turk, Martin S Angst, Raymond Dionne, Warren Wen

Pain· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression.
Aaron Yarlas, Kate Miller, Warren Wen, Shau Yu Lynch, Catherine Munera

Pain Pract· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain intensity and interference with functioning and well-being in subgroups of patients with chronic pain treated with once-daily hydrocodone tablets.
Adrian Bartoli, Edward Michna, Ellie He, Warren Wen

J Opioid Manag· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties.
Ram P Kapil, Alessandra Cipriano, Warren Wen, Shau Yu Lynch, Ellie He

Clin Ther· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
Warren Wen, Steve Sitar, Shau Yu Lynch, Ellie He, Steven R Ripa

Expert Opin Pharmacother· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
Warren Wen, Louise Taber, Shau Yu Lynch, Ellie He, Steven Ripa

J Opioid Manag· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis